Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1130

1.

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.

Amador-Licona N, Guízar-Mendoza J, Vargas E, Sánchez-Camargo G, Zamora-Mata L.

Arch Med Res. 2000 Nov-Dec;31(6):571-5.

PMID:
11257323
[PubMed - indexed for MEDLINE]
2.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
[PubMed - indexed for MEDLINE]
3.

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.

PMID:
11783602
[PubMed - indexed for MEDLINE]
4.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
[PubMed - indexed for MEDLINE]
5.

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M.

Diabetes Care. 1998 Dec;21(12):2135-9.

PMID:
9839106
[PubMed - indexed for MEDLINE]
6.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
[PubMed - indexed for MEDLINE]
7.

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ.

Diabetes Care. 1993 Jul;16(7):1035-8.

PMID:
8359098
[PubMed - indexed for MEDLINE]
8.

[Urinary albumin excretion by patients with type 2 diabetes mellitus. Effect of blood pressure and metabolic regulation].

Jungmann E, Carlberg C, Schallmayer M, Schumm-Draeger PM.

Med Klin (Munich). 1995 Jul 15;90(7):383-9. German.

PMID:
7675002
[PubMed - indexed for MEDLINE]
9.

Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.

Kosegawa I, Chen S, Awata T, Negishi K, Katayama S.

Clin Exp Hypertens. 1999 Apr;21(3):199-211.

PMID:
10225476
[PubMed - indexed for MEDLINE]
10.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
[PubMed - indexed for MEDLINE]
11.

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

Intern Med. 2007;46(22):1837-46. Epub 2007 Nov 16.

PMID:
18025765
[PubMed - indexed for MEDLINE]
Free Article
12.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.

PMID:
15220018
[PubMed - indexed for MEDLINE]
13.

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

Diabetes Obes Metab. 2006 Mar;8(2):197-205.

PMID:
16448524
[PubMed - indexed for MEDLINE]
15.
16.

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE.

J Hypertens. 2006 Oct;24(10):2047-55.

PMID:
16957566
[PubMed - indexed for MEDLINE]
17.

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.

Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P.

Metabolism. 2003 Jul;52(7):862-7.

PMID:
12870162
[PubMed - indexed for MEDLINE]
18.

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.

Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.

Intern Med. 2009;48(5):265-71. Epub 2009 Mar 2.

PMID:
19252346
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Hermann LS, Ranstam J, Vaaler S, Melander A.

Diabetes Obes Metab. 1999 Jul;1(4):227-32.

PMID:
11228758
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk